dbv technologies sa publicly owned french biopharmaceutical firm headquartered bagneux france dbv technologies known developing viaskin technology administering allergens antigens intact skin avoiding transfer blood viaskin peanut clinical development received fast track designation us food drug dbv technologies founded doctor pierrehenri benhamou specializing pediatric gastroenterology engineer bertrand dupont arts et métiers paristech paris professor christophe dupont head neonatology department saint vincent hospital founders provided initial startup approximately venture funding acquired december january march initial public offering nyse euronext exchange yielded daniel tassé presently serves ceo pascal wotling serves chief technical operations officer chief quality dbv technologies focused food allergies milk peanut pediatric allergies currently effective developed two products viaskin peanut treatment peanut allergies viaskin milk cows milk viaskin peanut treatment helps patients tolerate exposure peanut thus lowers risk systemic allergic reaction event accidental exposure clinical development program viaskin peanut received fast track designation us food drug administration dbv technologies developed patented innovative process epatch used determine allergies children readytouse standardised patch tests highly reliable conserve allergic agents best state september dbv technologies announced vipes viaskin peanut efficacy safety clinical trial viaskin peanut achieved successful results peanut allergy httpsenwikipediaorgwikidbvtechnologies